Evaluation of 2-Hydroxypropyl-β-Cyclodextrin as Solubilizing/Stabilizing Agent for Hydroxycamptothecin;

Preparation and in vitro drug-release behavior of hydroxycamptothecin semisolid lipid nanoparticles;

Preparation of hydroxycamptothecin liposomes and its encapsulation rate determination;

Clinical observation on Xisu HCPT plus radiotherapy in treating nasopharyngeal carcinomas;

Observation on efficacy of intraoperative submucosal injection of HCPT and postoperative bladder irrigation in treatment of bladder cancer;

The clinical investigation of nedaplatin with HCPT treating advanced esophageal cancer;

Change of survivin gene expression in gastric cancer cell line BGC-823 induced by hydroxycamptothecine;

Study on the effect of hydroxycamptothecine on cell line MUTZ-1 of human myelodysplastic syndromes in vitro;

Assay of Concentration of Hydroxycamptothecine in Plasma and Tissues of mouse by Fluorospectrophotometry;

Distribution of 10-hydroxycamptothecin emulsion and injection in the liver of rabbits;

Studies on the hydroxypropyl-β-cyclodextrin inclusion complexes of 10-hydroxycamptothecin;

Determination of 10-Hydroxycamptothecin by HPLC with Fluorescence Detection in Rabbit Plasma;

Quantitative analysis of hydroxycamptothecinum and its injection by HPLC;

Determination of Hydroxycamptothecinum by Capillary Zone Electrophoresis;

Voltammetric Behavior of Hydroxycamptothecinum at Single-Wall Carbon Nanotube Modified Electrode and Its Analytical Application;

Preparation of 10-hydroxycamptothecin Semisolid Lipid Nanoparticles and Investigation of Its Stability;

Inhibition of proliferation,anti-invasion and induction of apoptosis in highly metastasis human lung cancer cells by 10-hydroxycamptothecin;

Differentiation-inducing action of 10-hydroxycamptothecin on human hepatoma Hep G2 cells;